NCT04447053View on ClinicalTrials.gov

Sequential Belimumab and T-cell Based Therapy in SLE

PHASE4UnknownINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2025

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Belimumab Injection [Benlysta]

Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.

Trial Locations (1)

Unknown

RECRUITING

National University Hospital, Singapore

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

National University Hospital, Singapore

OTHER

NCT04447053 - Sequential Belimumab and T-cell Based Therapy in SLE | Biotech Hunter | Biotech Hunter